세계의 폐렴구균 백신 시장 전망(-2030년) : 제품 유형별, 백신 유형별, 연령대별, 유통 채널별, 최종 사용자별, 지역별 분석

According to Stratistics MRC, the Global Pneumococcal Vaccine Market is accounted for $8.80 billion in 2024 and is expected to reach $13.08 billion by 2030 growing at a CAGR of 6.8% during the forecast period. A pneumococcal vaccination is a prophylactic injection intended to guard against infections brought on by the Streptococcus pneumoniae bacterium, which can result in grave conditions like sepsis, meningitis, and pneumonia. Pneumococcal conjugate vaccines (PCV), such as PCV13, and pneumococcal polysaccharide vaccines (PPSV), such as PPSV23, are the two primary varieties. For vulnerable groups, particularly small children, the elderly, and those with compromised immune systems, these vaccinations are essential. They function by boosting the immune system's capacity to identify and attack pneumococcal bacteria.

According to the data published by the UN International Children's Emergency Fund (UNICEF) in November 2023, around 2,000 children were globally affected by pneumonia on a daily basis.

Market Dynamics:

Driver:

Growing prevalence of pneumococcal diseases

Pneumococcal vaccination demand is largely driven by the rising incidence of pneumococcal illnesses including meningitis and pneumonia. These infections are a major worldwide health burden, especially when they affect young children and the elderly. The availability of efficient vaccinations and growing awareness of the severe health risks linked to pneumococcal infections are driving market expansion. Pneumococcal vaccination demand is expected to increase gradually as global healthcare systems place a greater emphasis on public health campaigns and preventive measures.

Restraint:

Disruptions in supply chain

The pneumococcal vaccine industry is greatly impacted by production and supply chain disruptions, which may result in vaccine shortages, postponed vaccination schedules, and jeopardized public health initiatives. Manufacturing issues like scarce raw materials or strict quality control requirements that impede output can cause these interruptions. Additionally, timely vaccination distribution is hampered by logistical problems, especially in rural and low-income areas, such as poor cold chain infrastructure, transportation delays, or geopolitical factors.

Opportunity:

Increasing awareness and immunization programs

As government initiatives and campaigns by organizations like the World Health Organization (WHO) and UNICEF try to educate the public on the hazards of pneumococcal infections, rising awareness and immunization programs are important factors driving the pneumococcal vaccine market. To encourage early immunization and stop the spread of disease, these initiatives focus on high-risk populations, such as the elderly and newborns. Widespread vaccination campaigns increase access to vaccinations, which boosts global public health outcomes and contributes to market growth overall, particularly in low- and middle-income nations.

Threat:

High cost of vaccination

Pneumococcal vaccination's high price is a major barrier to availability for low-income groups and in nations with tight healthcare budgets. Advanced manufacturing techniques are needed to produce vaccines like PPSV23 and Prevnar 13, which raises the price. Even while some public health initiatives offer free or heavily discounted vaccines, financial constraints may still prevent universal availability. This cost barrier is particularly problematic in underdeveloped nations, as many people are discouraged from getting vaccinated due to the high out-of-pocket expenses, which affects overall vaccination rates and raises the risk of disease.

Covid-19 Impact

The pneumococcal vaccination market was greatly impacted by the COVID-19 pandemic, which carried with it both opportunities and challenges. Initially, vaccination programs were hampered by disruptions in healthcare services and supply chains, which resulted in delays in immunization schedules. Pneumococcal vaccinations, however, are in high demand as a result of the pandemic's increased awareness of respiratory illnesses and larger public health campaigns. The necessity of preventing pneumonia, especially in susceptible groups, prompted governments to step up immunization initiatives. As a result, the market is anticipated to expand as healthcare systems adjust and give pneumococcal vaccination equal weight with COVID-19 initiatives.

The pediatric segment is expected to be the largest during the forecast period

The pediatric segment is estimated to be the largest. Significant health risks are presented by the high prevalence of pneumococcal illnesses in newborns and young children, including meningitis and pneumonia. Demand is being increased by government initiatives and public health programs that highlight the significance of childhood vaccines. Further propelling market expansions in the pediatric sector are the availability of efficacious pneumococcal vaccines and parents' growing knowledge of the advantages of immunization.

The hospitals and clinics segment is expected to have the highest CAGR during the forecast period

The hospitals and clinics segment is anticipated to witness the highest CAGR during the forecast period. These healthcare centers are essential for delivering vaccinations, especially to susceptible groups including young children, the elderly, and people with weakened immune systems. Healthcare professionals are encouraged to offer pneumococcal vaccines by government programs that promote immunization and reimbursement policies for vaccine administration. Additionally, the growing prevalence of pneumococcal infections and the emphasis on preventative healthcare are fuelling the need for vaccines in clinics and hospitals.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to rising awareness of pneumococcal diseases, supported by government-backed immunization programs aimed at reducing child mortality rates. Increasing urbanization and improved healthcare infrastructure also facilitate vaccine access and distribution across diverse populations. Additionally, a growing geriatric population, particularly vulnerable to pneumococcal infections, amplifies demand. Partnerships with global health organizations and subsidies further boost vaccination rates, while local production efforts by companies in India and China help make vaccines more affordable and accessible.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period, owing to high awareness of immunization benefits, robust government healthcare programs, and comprehensive vaccine coverage under insurance plans. The established healthcare infrastructure enables wide access to vaccination, particularly for vulnerable groups like children, the elderly, and those with chronic illnesses. Ongoing research and development by key pharmaceutical players also support the introduction of advanced vaccines with broader serotype coverage. Additionally, public health initiatives and routine vaccination recommendations contribute to high vaccine adoption rates across the region.

Key players in the market

Some of the key players profiled in the Pneumococcal Vaccine Market include Pfizer Inc., Merck & Co., Inc., Sanofi S.A., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Astellas Pharma Inc., AstraZeneca, Bharat Biotech, SK Bioscience, Johnson & Johnson, Biological E. Limited, Sinovac Biotech Ltd., LG Chem Ltd., Panacea Biotec Ltd., Walvax Biotechnology Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Indian Immunologicals Ltd., and Novartis AG.

Key Developments:

In April 2024, Merck presented the results of the phase 3 clinical trial STRIDE-10 for an investigational 21-valent pneumococcal conjugate vaccine developed for adults.

In January 2024, Pfizer Inc. received marketing authorization from the Committee of Medicinal Products designed for Human Use (CHMP) of the European Medicines Agency (EMA) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC).

In April 2023, Pfizer Inc. received FDA approval for Prevnar 20 to prevent Invasive Pneumococcal Disease (IPD) in infants.

Product Types Covered:

• Prevnar 13 (PCV13)
• Pneumovax 23 (PPSV23)
• Vaxneuvance (PCV15)
• New and Pipeline Products
• Synflorix
• Pneumosil
• Other Product Types

Vaccine Types Covered:

• Pneumococcal Conjugate Vaccine (PCV)
• Pneumococcal Polysaccharide Vaccine (PPSV)

Age Groups Covered:

• Pediatric
• Adult
• Geriatric

Distribution Channels Covered:

• Distribution Partner Companies
• Non-Governmental Organizations (NGOs)
• Government Authorities

End Users Covered:

• Hospitals and Clinics
• Public Health Agencies and Immunization Programs
• Ambulatory Surgical Centers
• Home Healthcare Settings
• Retail Pharmacies
• Online Pharmacies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Pneumococcal Vaccine Market, By Product Type

• 5.1 Introduction
• 5.2 Prevnar 13 (PCV13)
• 5.3 Pneumovax 23 (PPSV23)
• 5.4 Vaxneuvance (PCV15)
• 5.5 New and Pipeline Products
• 5.6 Synflorix
• 5.7 Pneumosil
• 5.8 Other Product Types

6 Global Pneumococcal Vaccine Market, By Vaccine Type

• 6.1 Introduction
• 6.2 Pneumococcal Conjugate Vaccine (PCV)
• 6.3 Pneumococcal Polysaccharide Vaccine (PPSV)

7 Global Pneumococcal Vaccine Market, By Age Group

• 7.1 Introduction
• 7.2 Pediatric
• 7.3 Adult
• 7.4 Geriatric

8 Global Pneumococcal Vaccine Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Distribution Partner Companies
• 8.3 Non-Governmental Organizations (NGOs)
• 8.4 Government Authorities

9 Global Pneumococcal Vaccine Market, By End User

• 9.1 Introduction
• 9.2 Hospitals and Clinics
• 9.3 Public Health Agencies and Immunization Programs
• 9.4 Ambulatory Surgical Centers
• 9.5 Home Healthcare Settings
• 9.6 Retail Pharmacies
• 9.7 Online Pharmacies
• 9.8 Other End Users

10 Global Pneumococcal Vaccine Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Pfizer Inc.
• 12.2 Merck & Co., Inc.
• 12.3 Sanofi S.A.
• 12.4 GlaxoSmithKline plc
• 12.5 Serum Institute of India Pvt. Ltd.
• 12.6 Astellas Pharma Inc.
• 12.7 AstraZeneca
• 12.8 Bharat Biotech
• 12.9 SK Bioscience
• 12.10 Johnson & Johnson
• 12.11 Biological E. Limited
• 12.12 Sinovac Biotech Ltd.
• 12.13 LG Chem Ltd.
• 12.14 Panacea Biotec Ltd.
• 12.15 Walvax Biotechnology Co., Ltd.
• 12.16 Mitsubishi Tanabe Pharma Corporation
• 12.17 Indian Immunologicals Ltd.
• 12.18 Novartis AG